{
Levi Garraway

People

}
Roche's prasinezumab shows mixed results in Parkinson's disease study
Roche's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson's disease did not meet its primary endpoint of time to confirmed motor progression, though it showed promising trends in secondary endpoints, particularly in patients also treated with levodopa. The drug was well tolerated with no new safety concerns reported. Roche plans to present full results at an upcoming medical meeting, emphasizing the need for further exploration in the absence of disease-modifying treatments for Parkinson's.
Contract Pharma
Hoffmann-La Roche AG CHE Levi Garraway
Healthcare, Press Release
16:53 19.12.2024
Roche's Parkinson's drug prasinezumab fails to achieve significant trial results
Roche's Parkinson's drug, prasinezumab, has failed a Phase IIb trial, despite showing potential clinical efficacy in delaying motor progression. While the results indicated positive trends in secondary endpoints, they lacked statistical significance, prompting analysts to call the data "promising but leaves uncertainty." Roche plans to continue related studies and may consider a new trial to further explore the findings.
BioSpace
Hoffmann-La Roche AG Prothena Corp PLC CHE Levi Garraway
Healthcare, News Article
15:54 19.12.2024
roche and prothena's parkinsons antibody treatment fails in phase 2 trial
Roche and Prothena's Parkinson's antibody treatment, prasinezumab, failed to meet its primary endpoint in the phase 2b PADOVA study, although it showed a 16% delay in motor progression compared to placebo. The drug was well tolerated, and Roche plans to further evaluate the data and collaborate with health authorities on next steps. Parkinson's disease remains difficult to treat, with many therapies struggling to progress through clinical trials.
Biopharma-Reporter.com
United States Dollar UCB SA Hoffmann-La Roche AG Prothena Corp PLC Novartis AG BIOGEN IRL Levi Garraway Show more
Healthcare, News Article
15:39 19.12.2024
Roche's Parkinson's drug fails to meet primary trial objectives
Roche's experimental Parkinson's drug, prasinezumab, failed to meet its primary goal in a mid-stage trial, not significantly delaying motor symptom progression in early-stage patients. Despite this setback, the drug showed potential clinical efficacy and positive trends in other trial objectives. Roche plans to further evaluate the data and collaborate with health authorities on next steps.
Investing.com India
Novartis AG Hoffmann-La Roche AG BEL CHE Levi Garraway
Healthcare, News Article
14:44 19.12.2024
Roche receives EU approval for Vabysmo to treat major retinal conditions
Roche has received approval from the European Medicines Agency for Vabysmo, a 6.0 mg single-dose prefilled syringe, to treat neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This treatment addresses the needs of over nine million people in the EU, offering a more convenient administration method for ophthalmologists and potentially reducing the treatment burden for patients.
Yahoo Finance
Euro Hoffmann-La Roche AG CHE Levi Garraway
Healthcare, Press Release
13:00 14.12.2024
Roche gains EU approval for Vabysmo prefilled syringe to challenge Eylea
Roche has received EU approval for its Vabysmo prefilled syringe, targeting three retinal conditions that lead to blindness: wet age-related macular degeneration, diabetic macular oedema, and macular oedema following retinal vein occlusion. This ready-to-use formulation complements the existing vial option and aims to challenge Regeneron's Eylea, which currently dominates the market. With Vabysmo's sales surging 324% to $2.64bn, forecasts suggest it could reach $8.78bn by 2030, while Eylea's sales are expected to decline significantly.
Yahoo Finance
Euro Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG DEU CHE Levi Garraway
Healthcare, Market Report
13:19 13.12.2024
roche to acquire poseida for car t cell therapy development
Roche plans to acquire Poseida Therapeutics for $1.5 billion, focusing on allogeneic CAR-T cell therapies, including the investigational dual CAR-T therapy P-CD19CD20-ALLO1, currently in phase 1 trials for B-cell malignancies. The acquisition aims to enhance development in oncology, immunology, and neurology, with potential applications for multiple sclerosis and systemic lupus erythematosus. The deal is expected to close in Q1 2025.
Managed Healthcare Executive
United States Dollar Poseida Therapeutics, Inc. Hoffmann-La Roche AG USA Levi Garraway
Healthcare, Press Release
22:08 09.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.